111 results
8-K/A
EX-99.1
GMDAQ
Gamida Cell Ltd
5 Apr 24
Other Events
5:16pm
and who had no available matched donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT … %) and a safety profile similar to that reported previously.
On April 26, 2022, the Company announced that the FDA cleared its investigational new drug
8-K
EX-99.1
GMDAQ
Gamida Cell Ltd
14 Nov 23
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
12:00am
lymphoma enrolled in the first three cohorts in an ongoing multicenter Phase 1 study of GDA-201. The study is designed to evaluate safety and determine
8-K
EX-99.1
m8ddg3jn4ckyh
27 Sep 23
Regulation FD Disclosure
4:43pm
8-K
EX-1.1
yul3fv5v yit4k
21 Apr 23
Gamida Cell Announces Launch of Public Offering of Securities
7:19am
8-K
EX-99.1
sjs2afn09n4k5rbl
17 Apr 23
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
5:29pm
8-K
EX-99.1
8t6ue
12 Dec 22
Gamida Cell Announces Closing of $25 Million Financing with Highbridge
7:15am
8-K
EX-99.1
yzki60ttt4zqaqpubax
21 Nov 22
Gamida Cell Provides Regulatory Update on Omidubicel
5:20pm
8-K
EX-99.1
jspcr44s5i7mmij5nz7t
14 Nov 22
Gamida Cell Reports Third Quarter 2022 Financial Results
7:15am
8-K
EX-1.1
mpyulc rdcanc
30 Sep 22
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
4:02pm
424B5
l0adts
29 Sep 22
Prospectus supplement for primary offering
4:08pm
424B5
vx3e84gc87wyq
27 Sep 22
Prospectus supplement for primary offering
5:01pm